-
DE
A biosimilar is a biological medicine that is highly similar to an already approved reference biological product in terms of quality, efficacy, and safety.
Regular tips about health Regular tips about health Add as Preferred SourceA biosimilar is a biological medicine that is highly similar to an already approved reference biological product in terms of quality, efficacy, and safety.
A biosimilar is a biological medicine developed as a follow-on product to an already approved biological reference medicine, also known as the reference biologic. Biological medicines are manufactured using living cells -- such as bacteria, yeast, or mammalian cells -- and are inherently more complex than conventional chemically synthesised drugs. A biosimilar is highly similar to its reference product in structure, efficacy, and safety, but not identical, as biological manufacturing processes always involve a degree of natural variability.
Biosimilars are often confused with generic drugs. Generic drugs are exact chemical copies of small, synthetic molecules. Biosimilars, on the other hand, are follow-on versions of large, complex biological molecules such as monoclonal antibodies, erythropoietin, or insulin. Due to their biological complexity, biosimilars cannot be considered identical copies; instead, they must undergo extensive comparability studies to demonstrate similarity to the reference biologic.
In the European Union, biosimilars are regulated and approved by the European Medicines Agency (EMA). The approval process is rigorous and includes:
In the United States, biosimilars are regulated by the Food and Drug Administration (FDA) under the Biologics Price Competition and Innovation Act (BPCIA). Since the approval of the first biosimilar in Europe in 2006, the market has grown substantially worldwide.
Biosimilars are used across a wide range of medical specialties. Common therapeutic areas include:
Biosimilars offer significant advantages for both patients and healthcare systems:
A frequent topic surrounding biosimilars is interchangeability with the reference biologic. In the EU, an approved biosimilar is generally considered therapeutically equivalent to its reference product. However, any decision to switch from a reference biologic to a biosimilar -- or between biosimilars -- should always be made in consultation with the treating physician. Careful monitoring for adverse reactions is essential, particularly regarding immunogenicity (the potential of a medicine to trigger an unwanted immune response).
As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.
Average rating of 4.97 out of 5 stars
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®
Average rating of 4.85 out of 5 stars
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
Average rating of 4.88 out of 5 stars
Daily basic supply: the complete spectrum of micronutrients
Natural multivitamin complex for the immune system, energy, and central body functions
Average rating of 4.94 out of 5 stars
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.